Monte Rosa Therapeutics Stock

Monte Rosa Therapeutics Forward P/E

The Forward P/E Ratio of Monte Rosa Therapeutics (GLUE) as of Aug 6, 2026 is -35.37. In the previous year, Forward P/E Ratio was -18.79 — a change of 88.22% (lower).

Forward P/E

-35.37

YoY

88.22%

Last updated:

Forward P/E Ratio of Monte Rosa Therapeutics is 2026 -35.37 . Forward P/E Ratio of Monte Rosa Therapeutics was 2025 -18.79 . It decreases by 88.22% lower compared to the previous year.
Access this data via the Eulerpool API

Monte Rosa Therapeutics Stock analysis

What does Monte Rosa Therapeutics do? Monte Rosa Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Monte Rosa Therapeutics stock

Forward P/E Ratio of Monte Rosa Therapeutics is -35.37 in 2026.

Forward P/E Ratio of Monte Rosa Therapeutics changed from -18.79 to -35.37, representing a 88.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Monte Rosa Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Monte Rosa Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Monte Rosa Therapeutics

All Key Metrics — Monte Rosa Therapeutics